SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
FDA Commissioner Dr. Marty Makary delivers remarks after President Donald Trump made an announcement on drug pricing, Tuesday, September 30, 2025, in the Oval Office. (Official White House Photo by Joyce N. Boghosian)
Government
Signs of Frustration Build Between Kennedy and FDA Commissioner Makary
Top Trump administration officials have taken issue with Marty Makary’s management style, pointing to infighting between his appointees and the difficulty to get a hold of the FDA commissioner.
November 17, 2025
 · 
2 min read
 · 
Tristan Manalac
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Regulatory
Pressure On, Purpose Questioned as Second Round of FDA Priority Review Vouchers Revealed
Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and feasibility of the Commissioner’s National Priority Voucher program.
November 17, 2025
 · 
6 min read
 · 
Heather McKenzie
External view of Bristol Myers Squibb's office California
Cardiovascular disease
BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant
Bristol Myers Squibb and Johnson & Johnson will continue to test the asset in stroke and atrial fibrillation.
November 14, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Illustration showing finger pointing people to leave
Layoffs
Bayer Layoffs Continued in Q3 but CEO Says Cuts Should Be ‘Incremental’ Moving Forward
Bayer has let go of about 13,500 employees, including around 5,000 managers, since implementing a new operating model in early 2024. CEO Bill Anderson said in a recent earnings call that he expects a slower rate of headcount reduction moving forward.
November 14, 2025
 · 
1 min read
 · 
Angela Gabriel
Corporate headquarters of Novo Nordisk in Denmark
C-suite
UPDATE: Novo Foundation Completes Board Takeover After Shareholder Pushback
“As the future chair I will attend to the interests of not only the Novo Nordisk Foundation but all shareholders of the company,” incoming chair and former Novo Nordisk CEO Lars Rebien Sørensen said at the meeting held Friday.
November 14, 2025
 · 
5 min read
 · 
Annalee Armstrong
Contemporary art collage of woman sitting in the lotus position, cloud, pillows against the background of the night sky. Concept of healthy lifestyle and sport. Good and relaxing sleep. Copy space.
Mergers & acquisitions
Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel
A day after Pfizer closed its hotly contested Metsera deal, Lundbeck has made an unsolicited offer to steal Avadel Pharmaceuticals away from Alkermes.
November 14, 2025
 · 
1 min read
 · 
Annalee Armstrong
Investment mistakes, taxes, expenses, and unknown costs drain money, concept of Businessman carries a money bag with a big hole, banknotes falling out
Mergers & acquisitions
Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push
At $9.2 billion, the Cidara acquisition lands among the top 5 largest deals of the year.
November 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Feb 19, 2020 Foster City / CA / USA - Gilead corporate headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs
HIV
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV who are on complex treatment regimens, according to BMO Capital Markets.
November 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Different business strategies. Various solutions. Splitting opinions. Choosing way. Movement options. Separation of directions. Dilemma concept. Two diverging paths of arrows. 3d render
Vaccines
Pfizer Reportedly Planning To Divest BioNTech Stake
A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration.”
November 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS